Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). This trial is a double-blind, active control study evaluating treatment efficacy of oral torezolid phosphate 200mg once-daily for six days compared with oral linezolid (Zyvox, from Pfizer) 600mg twice-daily for 10 days. The primary efficacy endpoint is the cessation of spread of infected lesions and absence of fever at 48−72 hours following treatment initiation. Secondary endpoints include the sustained clinical response at the end of therapy visit, assessment of clinical response at all visits and clinical success at the post-treatment evaluation visit.
Torezolid phosphate is a second generation oral and IV antibacterial drug in the oxazolidinone class with activity against gram-positive bacterial pathogens, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
For more information call (858) 452-0370 or visit www.triusrx.com.